Clinical Trial Update: Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating Umbilical Cord Blood-derived CAR-engineered NK cells for B lymphoid malignancies has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-lymphoid Malignancies
• Chronic Lymphocytic Leukemia
• Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• CAR-NK cells derived from umbilical cord blood

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: B-Lymphoid Malignancies, Acute Lymphocytic Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-03-25